- Home
- NRDS vs BBOT Comparison
NRDS vs BBOT Comparison
Compare NRDS & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRDS | BBOT |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | NRDS | BBOT |
|---|---|---|
| Price | $10.49 | $9.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $14.33 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 665.2K | 252.5K |
| Earning Date | 05-05-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.42 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $836,600,000.00 | N/A |
| Revenue This Year | $10.13 | N/A |
| Revenue Next Year | $7.11 | N/A |
| P/E Ratio | $16.88 | ★ N/A |
| Revenue Growth | ★ 21.67 | N/A |
| 52 Week Low | $8.21 | $8.08 |
| 52 Week High | $16.24 | $14.87 |
Technical Indicators
Market Signals| Indicator | NRDS | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 49.99 | 53.01 |
| Support Level | $10.14 | $8.80 |
| Resistance Level | $11.02 | $12.36 |
| Average True Range (ATR) | 0.37 | 0.56 |
| MACD | 0.06 | 0.12 |
| Stochastic Oscillator | 54.87 | 94.08 |
Price Performance
Historical ComparisonAbout NRDS NerdWallet Inc.
Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. It gets revenue from fees paid by its financial services partners in the form of either revenue per action, revenue per click, revenue per lead and revenue per funded loan arrangements.
About BBOT BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.